Astragalus Membranaceus 480mg/day 10-Week Muscle Function Study NCT07552675
Summary
This double-blind, placebo-controlled, randomized clinical trial (NCT07552675) evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults during 8 weeks of progressive resistance training followed by 2 weeks of intensified training. Participants were randomized to receive either the herbal extract or placebo, with primary outcome measured as maximal voluntary isometric torque (MVIT) of the knee extensors and secondary outcomes including 1RM strength, knee range of motion, muscle soreness, and circulating biomarkers of muscle damage and inflammation. The study record was processed and made publicly available on ClinicalTrials.gov.
“This study evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults undergoing a structured resistance training program.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This is a clinical trial registry record documenting a completed double-blind, placebo-controlled randomized study (NCT07552675) evaluating Astragalus membranaceus (Astragali radix) extract at 480 mg/day for 10 weeks in healthy, moderately active adults undergoing structured resistance training. The trial assessed whether the herbal supplement could attenuate training-induced declines in muscle function, joint pain, and inflammatory markers, with maximal voluntary isometric torque of the knee extensors as the primary endpoint.
For compliance and regulatory professionals, this record represents a research study registration and results posting on ClinicalTrials.gov and does not itself create regulatory obligations. However, organizations conducting or sponsoring clinical research involving herbal or botanical supplements should note that this trial's completion and public results posting may inform future regulatory review of similar supplement-based interventions by FDA or other health authorities.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EFFECTS OF ASTRAGALUS MEMBRANACEUS ON MUSCLE FUNCTION
N/A NCT07552675 Kind: NA Apr 27, 2026
Abstract
This study evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults undergoing a structured resistance training program. Participants were randomized in a double-blind, placebo-controlled design to receive either Astragali radix extract (ASTRA) or placebo (PLA) during 8 weeks of progressive resistance training followed by 2 weeks of intensified training. The primary outcome was maximal voluntary isometric torque (MVIT) of the knee extensors. Secondary outcomes included one-repetition maximum (1RM) strength, knee range of motion, muscle soreness (VAS), and circulating blood biomarkers of muscle damage and inflammation.
Conditions: Healthy Adult
Interventions: Astragalus Membranaceus, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH/NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.